Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema.
Andrea Bauer, Lyn Guenther, Richard Woolf, Eydna Didriksen Apol, Douglas Maslin, Nanna Nyholm, Henrik Thoning, Marie Louise Schuttelaar
Contact Dermatitis 95(1) 91-99
摘要
摘要
BACKGROUND: Chronic Hand Eczema (CHE) is a multifactorial, fluctuating inflammatory disease of the hands and wrists that negatively impacts patients' health-related quality of life (HRQoL). OBJECTIVES: To assess the effects of delgocitinib cream versus cream vehicle on HRQoL. METHODS: DELTA 1 and DELTA 2 were phase 3 trials of identical design in which adults with moderate to severe CHE were randomised (2:1) to double-blind treatment with delgocitinib cream 20 mg/g or cream vehicle twice daily for 16 weeks. Data were pooled from both trials and changes in EQ-5D, Dermatology Life Quality Index (DLQI), and Hand Eczema Impact Scale (HEIS), including the HEIS Proximal Daily Activity Limitations (PDAL) and HEIS Embarrassment (Emb) subsets, were compared. RESULTS: Across the two trials, 639 patients were randomised to delgocitinib cream and 321 to cream vehicle. Delgocitinib cream resulted in significantly greater improvement in EQ-5D, DLQI, HEIS, HEIS PDAL, and HEIS Emb compared with cream vehicle at week 16 (all p < 0.001). More patients achieved clinically meaningful improvement from baseline in patient-reported outcomes at week 16 (all p < 0.001), and the mean time spent in an improved HRQoL state increased with delgocitinib cream. CONCLUSIONS: Delgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. CLINICAL TRIAL ID: DELTA 1 (NCT04871711) and DELTA 2 (NCT04872101).
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(4,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。